FDA Grants Orphan Drug Designation To GlycoMimetics’ GMI-1271 For Treatment of Acute Myleogenous Leukemia (AML)

Industry News

GMI-1271 has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of acute myeloid leukemia (AML).  GMI-1271 is an E-selectin antagonist in the pipeline of GlycoMimetics, a biotechnology company based in Gaithersburg, MD.  AML is an uncommon form of cancer of the blood and bone marrow characterized by rapid growth of abnormal white blood cells.  There are limitations with currently available treatments.  E-selectin is expressed on the surface of endothelial cells and has been shown to enhance adhesion of AML cancer cells in the vascular niche.  GlycoMimetics is currently recruiting patients in a Phase 1/2 clinical trial designed to evaluate the safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in adult patients with AML.




Subscribe to WXPress

Receive our newsletter and information on upcoming events.